Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a Healthcare company (Biotechnology) with a market capitalization of $602M. The Maz Rating grades it against the other companies in its sector.
Cullinan Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.28, Cullinan Therapeutics, Inc. trades at 2.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -59.1%, return on invested capital of -77.2% and a free cash flow yield of -27.3%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 7.43. Over the past 52 weeks the share price ranged from $8.23 to $23.19, with a beta of -0.01.
Cullinan Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.